Windsor Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$788K Buy
3,129
+11
+0.4% +$2.37K 0.2% 66
2026
Q1
$678K Buy
3,118
+319
+11% +$70.8K 0.19% 71
2025
Q4
$639K Buy
2,799
+164
+6% +$37.4K 0.18% 75
2025
Q3
$610K Buy
2,635
+7
+0.3% +$1.43K 0.17% 77
2025
Q2
$488K Buy
2,628
+9
+0.3% +$1.67K 0.14% 87
2025
Q1
$549K Buy
2,619
+49
+2% +$9.53K 0.17% 80
2024
Q4
$457K Buy
2,570
+8
+0.3% +$1.47K 0.14% 89
2024
Q3
$506K Buy
2,562
+128
+5% +$23.9K 0.15% 86
2024
Q2
$417K Buy
2,434
+9
+0.4% +$1.49K 0.13% 87
2024
Q1
$442K Buy
2,425
+116
+5% +$20K 0.14% 85
2023
Q4
$358K Buy
2,309
+10
+0.4% +$1.46K 0.12% 89
2023
Q3
$343K Buy
2,299
+8
+0.3% +$1.17K 0.12% 89
2023
Q2
$309K Buy
2,291
+9
+0.4% +$1.32K 0.1% 90
2023
Q1
$364K Buy
2,282
+8
+0.4% +$1.22K 0.13% 83
2022
Q4
$368K Buy
2,274
+577
+34% +$88.5K 0.13% 82
2022
Q3
$227K Buy
1,697
+8
+0.5% +$1.15K 0.08% 101
2022
Q2
$258K Buy
1,689
+8
+0.5% +$1.22K 0.09% 102
2022
Q1
$272K Buy
1,681
+8
+0.5% +$1.16K 0.08% 110
2021
Q4
$226K Buy
+1,673
New +$198K 0.07% 111
2021
Q3
Sell
-2,117
Closed -$238K 117
2021
Q2
$238K Buy
2,117
+243
+13% +$27.4K 0.08% 108
2021
Q1
$202K Sell
1,874
-490
-21% -$52.4K 0.07% 115
2020
Q4
$253K Buy
2,364
+9
+0.4% +$865 0.09% 104
2020
Q3
$206K Buy
2,355
+9
+0.4% +$847 0.09% 107
2020
Q2
$230K Buy
+2,346
New +$207K 0.1% 104
2020
Q1
Sell
-2,377
Closed -$210K 116
2019
Q4
$210K Buy
+2,377
New +$197K 0.09% 114
2019
Q1
Sell
-2,471
Closed -$227K 117
2018
Q4
$227K Sell
2,471
-8,292
-77% -$729K 0.12% 106
2018
Q3
$1.02M Sell
10,763
-359
-3% -$34K 0.46% 55
2018
Q2
$1.03M Buy
11,122
+565
+5% +$55.2K 0.48% 54
2018
Q1
$999K Sell
10,557
-1,492
-12% -$164K 0.47% 52
2017
Q4
$1.17M Sell
12,049
-1,461
-11% -$138K 0.54% 43
2017
Q3
$979K Hold
13,510
0.49% 43
2017
Q2
$979K Buy
13,510
+383
+3% +$25.7K 0.49% 43
2017
Q1
$855K Buy
13,127
+8,822
+205% +$555K 0.44% 46
2016
Q4
$269K Buy
4,305
+6
+0.1% +$366 0.15% 99
2016
Q3
$271K Sell
4,299
-8,645
-67% -$560K 0.15% 101
2016
Q2
$801K Buy
12,944
+360
+3% +$21.9K 0.47% 48
2016
Q1
$718K Buy
12,584
+3,310
+36% +$184K 0.45% 56
2015
Q4
$549K Buy
9,274
+622
+7% +$35.8K 0.34% 62
2015
Q3
$470K Buy
+8,652
New +$563K 0.28% 66
2014
Q1
Sell
-1,978
Closed -$104K 89
2013
Q4
$104K Buy
1,978
+5
+0.3% +$246 0.06% 118
2013
Q3
$88K Sell
1,973
-195
-9% -$8.64K 0.05% 125
2013
Q2
$90K Buy
+2,168
New +$94.8K 0.05% 111

Other funds holding ABBV

Windsor Capital Management's ABBV Position: Q2 2026 in Review

Windsor Capital Management increased its AbbVie (ABBV) stake by 0.35% in Q2 2026, buying an estimated $2.37K and bringing the position to 3,129 shares worth $788K. The position accounts for 0.2% of the portfolio, ranked #66.

Windsor Capital Management first reported a position in ABBV in Q2 2013 and has held it in 42 quarters since. The position peaked at $1.17M in Q4 2017. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Windsor Capital Management held 3,129 shares of AbbVie worth $788K as of Q2 2026.
  • Windsor Capital Management bought 11 AbbVie shares in Q2 2026, an estimated $2.37K.
  • AbbVie made up 0.2% of Windsor Capital Management's portfolio in Q2 2026, its #66 holding.
  • Windsor Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 42 quarters since.
  • Windsor Capital Management's AbbVie position peaked at $1.17M in Q4 2017.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Windsor Capital Management's 13F filing for Q2 2026, filed 8 Jul 2026.